Hypoxia-inducible factor 2α

A novel target in gliomas

Jaclyn J. Renfrow, Michael H. Soike, Waldemar Debinski, Shakti H. Ramkissoon, Ryan T. Mott, Mark B. Frenkel, Jann N Sarkaria, Glenn J. Lesser, Roy E. Strowd

Research output: Contribution to journalArticle

Abstract

Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

Original languageEnglish (US)
Pages (from-to)2227-2236
Number of pages10
JournalFuture Medicinal Chemistry
Volume10
Issue number18
DOIs
StatePublished - Sep 1 2018

Fingerprint

Glioma
Glioblastoma
Renal Cell Carcinoma
Transcription Factors
Up-Regulation
Stem Cells
Clinical Trials
Survival
endothelial PAS domain-containing protein 1
Hypoxia
Neoplasms

Keywords

  • cancer
  • glioblastoma
  • hypoxia
  • hypoxia-inducible factors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., ... Strowd, R. E. (2018). Hypoxia-inducible factor 2α: A novel target in gliomas. Future Medicinal Chemistry, 10(18), 2227-2236. https://doi.org/10.4155/fmc-2018-0163

Hypoxia-inducible factor 2α : A novel target in gliomas. / Renfrow, Jaclyn J.; Soike, Michael H.; Debinski, Waldemar; Ramkissoon, Shakti H.; Mott, Ryan T.; Frenkel, Mark B.; Sarkaria, Jann N; Lesser, Glenn J.; Strowd, Roy E.

In: Future Medicinal Chemistry, Vol. 10, No. 18, 01.09.2018, p. 2227-2236.

Research output: Contribution to journalArticle

Renfrow, JJ, Soike, MH, Debinski, W, Ramkissoon, SH, Mott, RT, Frenkel, MB, Sarkaria, JN, Lesser, GJ & Strowd, RE 2018, 'Hypoxia-inducible factor 2α: A novel target in gliomas', Future Medicinal Chemistry, vol. 10, no. 18, pp. 2227-2236. https://doi.org/10.4155/fmc-2018-0163
Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB et al. Hypoxia-inducible factor 2α: A novel target in gliomas. Future Medicinal Chemistry. 2018 Sep 1;10(18):2227-2236. https://doi.org/10.4155/fmc-2018-0163
Renfrow, Jaclyn J. ; Soike, Michael H. ; Debinski, Waldemar ; Ramkissoon, Shakti H. ; Mott, Ryan T. ; Frenkel, Mark B. ; Sarkaria, Jann N ; Lesser, Glenn J. ; Strowd, Roy E. / Hypoxia-inducible factor 2α : A novel target in gliomas. In: Future Medicinal Chemistry. 2018 ; Vol. 10, No. 18. pp. 2227-2236.
@article{7bfda852aec0424cbdd528a48df08fce,
title = "Hypoxia-inducible factor 2α: A novel target in gliomas",
abstract = "Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.",
keywords = "cancer, glioblastoma, hypoxia, hypoxia-inducible factors",
author = "Renfrow, {Jaclyn J.} and Soike, {Michael H.} and Waldemar Debinski and Ramkissoon, {Shakti H.} and Mott, {Ryan T.} and Frenkel, {Mark B.} and Sarkaria, {Jann N} and Lesser, {Glenn J.} and Strowd, {Roy E.}",
year = "2018",
month = "9",
day = "1",
doi = "10.4155/fmc-2018-0163",
language = "English (US)",
volume = "10",
pages = "2227--2236",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "18",

}

TY - JOUR

T1 - Hypoxia-inducible factor 2α

T2 - A novel target in gliomas

AU - Renfrow, Jaclyn J.

AU - Soike, Michael H.

AU - Debinski, Waldemar

AU - Ramkissoon, Shakti H.

AU - Mott, Ryan T.

AU - Frenkel, Mark B.

AU - Sarkaria, Jann N

AU - Lesser, Glenn J.

AU - Strowd, Roy E.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

AB - Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

KW - cancer

KW - glioblastoma

KW - hypoxia

KW - hypoxia-inducible factors

UR - http://www.scopus.com/inward/record.url?scp=85052883641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052883641&partnerID=8YFLogxK

U2 - 10.4155/fmc-2018-0163

DO - 10.4155/fmc-2018-0163

M3 - Article

VL - 10

SP - 2227

EP - 2236

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 18

ER -